OCTOBER 2023LIFE SCIENCES REVIEW8An interview with Li Chen, Vice President & General Manager, Biologics, West Pharmaceutical Services, Inc.1. In your opinion, how has the Immunotherapy landscape evolved over the years? What are some of the advantages of the current technological evolution?Technology development for immunotherapy has evolved in several ways. The technology behind life changing living drugs (CAR T-cell therapies) innovated from the need to track their manufacturing and transportation activities, and medical devices fit-for-use for advanced therapies in containment and delivery. Each of these aspects of technology development must integrate with each other to realize the industry's goal of affordable, curative therapies for all to access equally. In this light, administration technology is behind the biological technical revolution and could evolve from a simple syringe, flexible bag, and cannula to a more personalized device tailored to meet patient needs and the various demands on healthcare staff. Additional cell-based immunotherapies are also in development, aiming to provide treatment options to those who currently have none or patients who are not able to achieve complete response from existing treatment. Cancer often develops mechanisms to evade immune response. One such mechanism engages the natural breaks on T-cells to stop it from attacking. Today, the best-known immunotherapy is designed to release the breaking mechanism, called checkpoint inhibition, which allow T-cells to go at full speed to destroy what shouldn't Li Chen has been working as a Vice President and General Manager, Biologics at West Pharmaceutical Services for 2 years. She oversees the development and execution of strategies and plans within the organization. She also establishes guidelines, policies and protocols to promote efficient operations.LEVERAGING TECHNOLOGY TO BOOST IMMUNOTHERAPYLi ChenIN MY OPINION
< Page 7 | Page 9 >